07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

Altair Nanotechnologies, Spectrum Pharmaceuticals deal

The partners added non-human indications to a 2005 deal that granted Spectrum exclusive, worldwide rights to develop and commercialize Altair's RenaZorb family of compounds for all human indications. The oral lanthanum-based phosphate binding compound is...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Altair management update

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Supply/Service   Transitioned: Terry Copeland to president and CEO, from interim president  ...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Altair board of directors update

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Supply/Service   Appointed: Robert van Schoonenberg, EVP, chief legal officer and secretary at Avery Dennison Corp.  ...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Company News

Altair management update

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Transitioned: Terry Copeland to interim president, while remaining VP of operations at Altair's power and energy group; he replaces President and CEO Alan...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Altair management update

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Hired: Jeffrey McKinney as VP and chief patent counsel, formerly special counsel at Sheppard Mullin Richter & Hampton LLP  ...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Company News

Altair scientific advisory board update

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Appointed: Andrew Burke  ...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Company News

Altair Nanotechnologies scientific advisory board update

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Appointed: John Midgley, CEO of Ultradots Inc.  ...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals, Altair deal

The companies resolved their arbitration related to milestone payments under a 2005 deal in which SPPI received exclusive worldwide rights to develop and market ALTI's RenaZorb lanthanum-based phosphate binding compound for kidney disorders (see BioCentury,...
08:00 , Mar 14, 2005 |  BC Week In Review  |  Company News

Altair management update

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Renal   Departed: Rudi Moerck as president  ...
08:00 , Feb 7, 2005 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals, Altair deal

Spectrum received exclusive worldwide rights develop and market ALTI's RenaZorb . The lanthanum-based phosphate binding compound is in preclinical development to control phosphate levels in patients with chronic kidney disease (CKD) and hyperphosphatemia associated with...